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ABSTRACT 
 
Newborn calves still often suffer from iron deficiency. This state damages their growth and 
development - to some extent, due to the development of pathological changes in hemostasis. 
Thereby, both veterinary science and cattle physiology give great scientific and practical significance 
to the search of approaches to effective correction of new-born calves’ hemostasis pathology 
connected with iron deficiency. It seemed to be perspective to evaluate the influence degree of 
ferroglukin, traditionally applied at iron deficiency, in combination with metabolism stimulators 
(fosprenil and hamavit) on new-born calves’ indices of hemostasis system. During our study it was 
established that new-born calves with iron deficiency were also characterized by decreased plasma 
antioxidant protect-ability, intensity of lipids’ peroxidation processes, increase of platelets’ 
hemostatic activity and blood coagulation system along with the decrease of vascular wall’s ability to 
bind it. In our study we found that combination of ferroglukin, fosprenil and hamavit given to new-
born calves with iron deficiency showed improved plasma antioxidant and lipid peroxidation activity. 
Normalization of platelet activity, positive dynamics of hemostasis vascular and plasma components 
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were also observed. Iron deficiency of new-born calves can be considered as the model of 
hemostasis abnormality. With its help we could try different means and their combinations to cure 
the pathology of hemostasis. The obtained results allowed us to consider the usage of fosprenil and 
hamavit combination on the background of ferroglukin to be sufficient for reducing the pathology of 
hemostasis in newborn calves with iron deficiency. 
 
 
Keywords: New-born calves; iron deficiency; hemostasis system; ferroglukin; fosprenil; hamavit. 
 
1. INTRODUCTION 
 
The aims of durable and well-planned 
researches in the field of cattle physiology are 
conducted to accelerate the processes of its 
growth, to increase its productivity [1], to work 
out the ways of modern prophylaxis of different 
abnormalities and to create approaches for 
curing the developed pathology [2]. It is very 
important to accumulate knowledge about 
different sides of calves’ physiological processes 
at the very beginning of their ontogenesis [3] 
because of special significance of the phase of 
birth. It lays the foundation for milk and meat 
productivity of cattle. At the present moment it is 
assumed that the leading role in support of 
hemostasis during the whole ontogenesis 
belongs to blood and its hemostatic mechanisms 
influencing heavily the way of individual 
development [4,5] with the help of 
hemocirculation  processes. So, activity changes 
of hemostasis processes change activity of 
hemocirculation in tissues and organs, and, thus, 
influence the common state of a body [6]. In 
previous researches it was found that quick 
increase of hemostasis components’ activity able 
to lead to microcirculation abnormalities [7] could 
take place in homeostasis deviations, especially 
in case of a young organism. Basic studies in this 
field were conducted on a human being [8,9,10]. 
Basing on their results we managed to make a 
conception of age-specific dynamics of 
hemostasis components’ activity [11,12], its most 
vulnerable mechanisms and the potential of 
different variants of impact on a body aiming at 
haemostatic processes’ optimization. Because      
of great social significance of thrombosis 
development in case of cordial pathology [13,14] 
many researchers’ attention is still devoted to 
haemostatic changes in given patients 
[15,16,17]. They investigated different aspects   
of hemostasiopathy pathogenesis of cordial 
diseases. As a result, the possibility of its 
correction was found. It can be done not only 
with the help of medicines [18,19], but also with 
the help of traditionally applied means [20,21]. It 
has great significance for biological 
investigations as it allows minimizing application 
of medicines. 
 
Taking all this into account, we have large 
scientific and practical interest to the estimation 
of hemostasis state of new-born calves in 
conditions of different dysfunctions. We are also 
eager to find some ways of a body state 
correction which can positively influence the 
manifestations of hemostasiopathy. We thought 
to be perspective to take iron deficiency as a 
model of hemostasis abnormality, as it was often 
found in new-born calves, and tried to work out 
an effective way of correction of all the 
hemostasis system components. The given 
model seemed to be justified as it was to result in 
the decrease of hemoglobin content in blood and 
activity lowering of iron-bearing enzymes which 
suppressed protein synthesis and activity of 
cellular functions [22]. Furthermore, iron 
deficiency was estimated as a state 
accompanied by changes in the whole body’s 
activity. It also led to abnormalities in all the 
components of hemostasis system. 
 
Moreover, the investigations, aimed at curing 
hemostasiopathy in calves with iron deficiency, 
had a great scientific and practical significance. 
Worked out at the given stage varients of evident 
decrease of hemostasis abnormalities can serve 
the basis for the following creation of              
correction complexes able to be effective in            
the field of hemostasiopathy reduction in               
new-born calves at many diseases. Clearing              
out the impact of combination of iron-bearing 
substance [23], fosprenil [24] and hamavit                  
[25] (which showed earlier their high biological 
activity as far as separate hemostasis 
components are concerned) has serious 
perspectives for reducing iron deficiency. In 
addition to this, the purpose of our research was 
to find the evident ability of ferroglukin, fosprenil 
and hamavit combination to correct hemostasis 
system activity of new-born calves with iron 
deficiency. 
  
  
 
 
Yu; ARRB, 14(2): 1-8, 2017; Article no.ARRB.33617 
 
 
 
3 
 
2. MATERIALS AND METHODS 
 
2.1 Materials 
 
The study used 34 newborn calves with 
manifestations of erythrogenesis and decrease of 
iron content in their bodies (serum iron 12.3±0.10 
umol/l, siderocytes 1.6±0.05%, hemoglobin 
95.0±0.29 g/l, erythrocytes 4.1±0.13x1012/l). The 
control group consisted of 29 healthy newborn 
calves. 
 
All the investigations in the present study were 
conducted in full correspondence with ethical 
norms and recommendations on humanization of 
work with laboratory animals containing "The 
European Convent on the protection of 
vertebrate animals used for experiments or in 
other scientific purposes" (Strasbourg, 1986). 
 
2.2 Methods 
 
The state of lipids’ peroxidation (LPO) in animals’ 
plasma was found out according to the quantity 
of thiobarbituric acid –active products in it with 
the help of a set produced by the firm “Agat-Med” 
(Russia) and acylhydroperoxides with the 
account of antioxidant activity level of the liquid 
part of blood [26]. Platelets’ number in calves’ 
blood was found by their calculation in Gorjaev’s 
box. Platelets’ aggregation was registered by 
visual micromethod [10] with some inductors: 
with ADP (0.5x10-4 M), with thrombin (0.125 
un/ml), with collagen (dilution 1:2 of the main 
suspension), with ristomicin (0.8 mg/ml), with 
epinephrine (5x10-6 M) in plasma with 
standardized quantity of platelets in it             
(200x109 tr). 
 
Disaggregative abilities of vascular wall were 
determined with the help of a test with temporal 
venous occlusion on the basis of visual 
micromethod of platelet aggregation registration 
[10] with all the applied inductors. We calculated 
the value of vascular wall disaggregative activity 
index (VWDAI). It was made by dividing the 
platelets’ aggregation period on the background 
of venous deadlock on the time of platelets’ 
aggregation appearance without it. The index 
value of vascular wall anticoagulation activity of 
examined calves was also calculated by dividing 
antithrombin III activity after venous occlusion on 
its value before it [27]. Vascular control over 
fibrinolytic blood activity was found out by 
calculating the index value of vascular wall 
fibrinolytic activity. We divided the period of 
euglobulinlysis before occlusion on lysis period 
after it [27]. 
The state of plasma hemostasis was evaluated 
according to duration of activated partial 
thromboplastinic period (APTP), prothrombinic 
period and thrombin period with the help of 
generally applied methods [27]. 
 
The correction of iron deficiency state of new-
born calves was made by applying ferroglukin 
intramuscularly, once a day from the calculation 
of 15 mg of iron on 1 kg of body mass, fosprenil- 
0.1 mg/kg intramuscularly in the morning as 
liquid feeding for 6 days and hamavit– 0.1 ml/kg 
intramuscularly as liquid feeding for 6 days 
beginning simultaneously with ferroglukin 
application. The evaluation of the animals’ health 
was made twice – at their birth and on the 7th day 
of life. Because of the absence of reliable 
differences between the results of both studies, 
control values of each index were presented by 
one figure –a simple average between them. 
Examination of calves with iron deficiency was 
conducted twice –at their birth and on the next 
day after correction finish (the 7th day of life). The 
results were processed by Student's criterion (t). 
Statistical processing of received information was 
made with the help of a programme package 
“Statistics for Windows v. 6.0”, “MicrosoftExcel”. 
Differences in data were considered reliable in 
case of р<0.05. 
 
3. RESULTS AND DISCUSSION 
 
The examined newborn calves with iron 
deficiency had usual for the given state 
weakness, limpness, absence of interest to the 
environment, paleness of rhino scope and slime 
layers. These animals also had increased LPO 
activity in plasma (acylhydroperoxide 3.42±0.012 
D233/1 ml, thiobarbituric acid- active products 
5.19±0.019 umol/l at value depression of 
antioxidant activity of blood liquid part 
22.0±0.23%). The control values of these indices 
were equal to 1.45±0.010 D233/1 ml, 3.46±0.012 
umol/l and 33.7±0.15%, respectively. 
 
Platelets’ quantity in newborn calves’ blood was 
equal to norms. Besides, platelets’ aggregation 
of animals with iron deficiency turned out to be 
reliably increased (table). Their earliest platelets’ 
aggregation appeared in response to collagen  
(19.8±0.15s), a bit later it developed with ADP 
and with ristomicin, then later in response to 
thrombin (37.9±0.21s). The latest platelets’ 
aggregation of calves with iron deficiency 
appeared under epinephrine impact 
(68.2±0.25s). 
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Table 1. Parameters of hemostasis in newborn calves with iron deficiency treated with 
ferroglukin, fosprenil and hamavit 
 
Consider indicators Calves with iron deficiency, n=34, M±m control,  
n=29, M±m outcome after the correction 
Platelet aggregation with ADP, s   25.0±0.10 29.6±0.05  
р1<0.05  
40.2±0.08 
р<0.01 
Platelet aggregation with 
collagen, s 
19.8±0.15 24.9±0.04  
р1<0.05 
31.4±0.08 
р<0.01 
Platelet aggregation with 
thrombin, s 
37.9±0.21 46.6±0.16 
р1<0.05 
53.8±0.07 
р<0.01 
Platelet aggregation with 
ristomicin, s 
22.5±0.16 38.6±0.07 
р1<0.01 
48.0±0.12 
р<0.01 
Platelet  aggregation with 
epinephrine, s 
68.2±0.25 85.3±0.06 
р1<0.01 
97.6±0.06 
р<0.01 
VWDAI with ADP 1.44±0.003 1.58±0.003 
р1<0.01 
1.68±0.008 
р<0.01 
VWDAI with collagen 1.33±0.005 1.46±0.008 
р1<0.01 
1.58±0.003 
р<0.01 
VWDAI with thrombin 1.38±0.007 1.47±0.004 
р1<0.01 
1.52±0.006 
р<0.01 
VWDAI with ristomicin 1.40±0.004 1.43±0.009 1.51±0.006 
р<0.05 
VWDAI with epinephrine 1.42±0.006 1.49±0.003 
р1<0.05 
1.64±0.004 
р<0.01 
Index value of vascular wall 
anticoagulation activity 
1.23±0.006 1.28±0.005 1.31±0.004 
р<0.05 
Index value of vascular wall 
fibrinolytic activity 
1.23±0.009 1.30±0.006 
р1<0.05 
1.39±0.010 
р<0.01 
Activated partial thromboplastin 
period, s 
27.0±0.29 39.8±0.33 
р1<0.01 
39.7±0.31 
р<0.01 
Prothrombin period, s 12.2±0.25 17.4±0.30 
р1<0.01 
17.4±0.22 
р<0.01 
Thrombin period, s 15.8±0.19 17.3±0.15 
р1<0.05 
17.2±0.21 
р<0.05 
Legend:  p - reliability of differences of indicators between the control and the initial state of the calves with iron 
deficiency, p1 – reliability of dynamics of indicators in calves with iron deficiency on the background of correction 
 
Newborn calves with iron deficiency had VWDAI 
decrease in relation to all the applied inductors 
(Table 1). The lowest VWDAI value belonged to 
collagen, a bit higher VWDAI value was for 
thrombin, yet higher VWDAI value was with 
ristomicin, ADP and epinephrine. The examined 
animals with iron deficiency had decrease of 
vascular wall anticoagulant ability. It was found 
according to the decrease of the index value of 
anticoagulant activity of a vascular wall. 
Fibrinolytic features of these animals’ vessels 
were also weakened – the index of vascular     
wall fibrinolytic activity was decreased on    
13.0%. 
 
Newborn calves with iron deficiency were also 
characterized by APTP (42.3%) and prothrombin 
period (42.6%) increase accompanied by some 
intensity of thrombin period (8.7%). 
Conducted correction of calves’ state provided 
them with iron deficiency improvement of the 
common state and increase of their serum iron 
level to the control values (29.3±0.12 umol/l). On 
the background of application of ferroglukin, 
fosprenil and hamavit combination examined 
calves had evident decrease of 
acylhydroperoxides (2.16±0.010 D233/1 ml, 
p<0.01) and thiobarbituric acid-active products 
(4.12±0.014 umol/l, p<0.01) in plasma content at 
the increase of antioxidant activity to 29.1±0.09% 
(p<0.01). 
 
The process of correction of animals’ iron 
deficiency was accompanied by invariability of 
platelets’ quantity in their blood and some 
slowdown of platelets’ aggregation. Besides, 
animals’ platelets most actively responded to 
aggregation with collagen, ADF and ristomicin, 
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less actively – with thrombin and adrenaline 
addition into plasma (Table 1). 
 
The examined calves after conducted application 
had evident VWDAI increase in relation to all the 
applied inductors (Table 1). The minimum value 
was VWDAI value with thrombin. Other VWDAI 
values were a bit higher and had a tendency to 
approaching the control values. Newborn calves 
with iron deficiency received iron preparation in 
combination with metabolically active means and 
had a tendency to the index increase of vascular 
wall anticoagulant activity and the index rise of 
vascular wall fibrinolytic activity on 9.5%. 
 
Thanks to complex application we reached APTP 
slowdown on 42.6% at simultaneous decrease of 
prothrombin period on 42.6%. It allowed them to 
get normalized. Besides, the value of thrombin 
period, defining the activity of fibrinogen 
transition into fibrin, increased on 8.9% and 
reached the control level. 
 
Realization of genetically determined growth and 
development processes of living beings takes 
place under constant influence of numerous 
external and internal factors of environment [28]. 
Physiological peculiarities of their influence are 
mostly expressed by the optimum of living 
beings’ blood content [29]. It is especially 
essential for the activity of hemostasis system 
components [30]. Besides, any abnormalities in a 
body are accompanied by negative dynamics    
of hematological indices [31,32] including 
parameters of hemostasis system [33,34]. It 
became clear, that on the basis of 
hemostasiopathy development we found not only 
iron deficiency but also depression of plasma 
antioxidant protection. Previous research showed 
that it caused LPO activation in it. Increase of 
peroxidation in plasma damaged structures of 
blood platelets and vessels and affected their 
functions [35,36]. Acceleration of platelet 
aggregation of newborn calves with iron 
deficiency pointed at the increase of their 
receptors’ sensibility to outside stimulating 
impacts. Besides, active development of platelet 
aggregation in response to ristomicin was to be 
regarded as consequence of their sensibility 
increase to von Willebrand Factor. Besides, 
acceleration of platelet aggregation, developing 
in these animals indirectly, told about the 
increase of exchange processes of arachidonic 
acid with surplus thromboxan A2 formation [37] in 
their blood. 
 
Weakening of vascular hemostasis functional 
abilities of animals with iron deficiency became 
apparent at lowering of vessels’ disaggregative 
features. It was evidently caused by the 
decrease of generation of prostacyclin and nitric 
oxide molecules [38] in their walls. At the same 
time, the examined calves had weakening of 
vessels’ anticoagulant and fibrinolytic abilities 
because of production depression of 
anticoagulant – antithrombin III and tissue 
activators of plasminogen in them. 
 
Found acceleration of prothrombin period of 
newborn calves with iron deficiency pointed at 
the evident activity intensity of outer mechanism 
of plasma hemostasis starting. Its basis was 
activity increase of coagulation factors 
participating in it [39]. Early APTP appearance 
was connected with activation of coagulation 
factors participating in the inner way of 
hemocoagulation. Acceleration of blood 
coagulation final stage pointed at the intensive 
change of fibrinogen into fibrin in examined 
calves [17]. 
 
Application of ferroglukin, fosprenil and hamavit 
combination made newborn calves with iron 
deficiency feel saturated with iron. It also brought 
positive dynamics of red blood and common 
animals’ state indices. The impact on examined 
calves’ bodies was accompanied by lowering of 
their LPO processes intensity in plasma what 
weakened its damaging influence on 
endothelium and liver platelets. After the 
application of ferroglukin, fosprenil and hamavit 
combination platelet aggregation of calves with 
iron deficiency weakened. It was mostly the 
consequence of positive impact of these means’ 
combination on innerplatelet LPO, receptor and 
postreceptor platelets’ functioning mechanisms 
[38]. Developing in these conditions increase of 
the period of platelet aggregation as a response 
to ristomicin, pointed at lowering of adhesion 
cofactor – von Willebrand Factor [19] in these 
calves’ blood. 
 
In the result of applied impact animals, having           
at the beginning iron deficiency, got some 
strengthening of disaggregation, anticoagulant 
and fibrinolytic vessels’ features. On the basis of 
found changes, though, the control level of 
production intensity of prostacyclin, nitric oxide, 
antithrombin III and tissue activator plasminogen 
[29] in vascular endothelium of these calves 
wasn’t reached. 
 
Found in examined animals on the background 
of applied impact slowdown of prothrombin 
period reflected normalization of 
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hemocoagulation processes along the outer way 
mainly on behalf of production lowering of factors 
participating in it in liver [1]. Happened on the 
background of correction slowdown of initially 
accelerated APTP was accompanied by 
weakening of generation activity, normalization of 
coagulation factors and especially factor XII. 
Happened duration slowdown of 
hemocoagulation final stage, what was judged by 
thrombin period, pointed at weakening of 
fibrinogen transformation into fibrin till control 
level in examined calves. 
 
As the result of our investigation it became clear 
that in the case of application of ferroglukin, 
fosprenil and hamavit combination to newborn 
calves with iron deficiency, we could provide 
normalization of hemocoagulation and positive 
dynamics of the rest hemostasis system 
components. 
 
4. CONCLUSION 
 
Iron deficiency of newborn calves can be 
considered as the model of hemostasis 
abnormality. With its help we can try different 
means and their combinations to cure 
hemostasiopathy. It is caused by the facts that 
newborn calves with iron deficiency are 
characterized by lowering of blood plasma 
antioxidant protection, intensity of LPO 
processes in it, increase of platelet hemostatic 
activity and hemocoagulation. It is also 
accompanied by depression of vascular wall 
abilities to inhibition of these processes. Because 
of the presence of iron deficiency in newborn 
calves it was justified to use iron preparation. For 
strengthening of its impact on a body there   
were prescribed stimulating metabolism and 
anabolism means – fosprenil and hamavit. In our 
study we found that in case of their application to 
newborn calves it’s possible to strengthen 
antioxidant protection, weaken LPO activity, 
decrease platelet activity, produce positive 
dynamics of hemostatic features of vascular wall 
and normalize plasma hemostasis. The received 
results allowed us to consider the usage of 
combination of fosprenil and hamavit on the 
background of ferroglukin to be sufficient for 
reducing of hemostasiopathy in new-born calves 
with iron deficiency. 
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